Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in decades has failed a pivotal test intended to support expanding its use ...

The shocking murder of former Karnataka Police chief Om Prakash, allegedly by his wife Pallavi, has triggered widespread outrage. Pallavi was arrested following a complaint by their son, Kartikesh ...

Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on ...

A New York judge found that the Art Institute of Chicago’s drawing by Egon Schiele had been looted from an Austrian Jew who died in a concentration camp. By Graham Bowley and Tom Mashberg A ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with inadequately controlled schizophrenia did not achieve statistically ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

Bleeding Cool scooped the news that Marvel was to revive its Bring On The Bad Guys brand, back in February. Now Marvel Comics is dropping full details ahead of its July 2025 solicitations later today.

A New York judge ruled on Wednesday (23 April) that the Art Institute of Chicago (AIC) must return a Nazi-looted Egon Schiele drawing, the latest development in a yearslong battle between the ...